18/10/2026
Retatrutide is an investigational medication designed to activate three hormone receptors involved in regulating metabolism and appetite: GIP, GLP-1 and glucagon. By acting on these pathways, the drug aims to influence hunger, food intake, blood glucose regulation and energy metabolism.
This approach builds on earlier medications that target one or two of these hormone pathways. Clinical research has reported substantial weight loss among participants receiving retatrutide, making it a subject of interest in the development of treatments for obesity and related metabolic conditions.
However, weight-loss results from clinical trials do not mean the medication is suitable for everyone. Researchers must continue evaluating its long-term effectiveness, safety, adverse effects and appropriate use. Retatrutide should not be confused with an approved, routinely available weight-loss medicine, and it does not replace the importance of sustainable dietary habits, physical activity and individualised medical care.
..
https://www.zmescience.com/medicine/triple-agonist-drug-retatrutide-patients-lose-weight/